{"id":404515,"date":"2025-07-23T11:35:16","date_gmt":"2025-07-23T09:35:16","guid":{"rendered":"https:\/\/medizinonline.com\/?p=404515"},"modified":"2025-07-23T13:06:43","modified_gmt":"2025-07-23T11:06:43","slug":"ladmission-par-les-caisses-maladie-dun-traitement-de-premiere-ligne-de-la-llc-offre-des-occasions-de-beneficier-dune-plus-longue-periode-sans-traitement-1-2","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/ladmission-par-les-caisses-maladie-dun-traitement-de-premiere-ligne-de-la-llc-offre-des-occasions-de-beneficier-dune-plus-longue-periode-sans-traitement-1-2\/","title":{"rendered":"L\u2019admission par les caisses-maladie d\u2019un traitement de premi\u00e8re\u00a0ligne de la LLC offre des occasions de b\u00e9n\u00e9ficier d\u2019une plus longue p\u00e9riode sans traitement [1, 2]"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>L\u2019inhibiteur de BCL-2 Venclyxto\u00ae (v\u00e9n\u00e9toclax; Ven) est autoris\u00e9 en Suisse en association avec l\u2019obinutuzumab (Obi) depuis le 16&nbsp;novembre&nbsp;2023 comme traitement de premi\u00e8re&nbsp;ligne de la leuc\u00e9mie lympho\u00efde chronique (LLC) [2]. Les donn\u00e9es \u00e0 6&nbsp;ans de l\u2019\u00e9tude pivot CLL14 offrent aux patientes et patients atteints de LLC la perspective d\u2019une p\u00e9riode sans traitement de plus de 5&nbsp;ans apr\u00e8s moins d\u2019un&nbsp;an de traitement combin\u00e9 par Venclyxto\u00ae&nbsp;+&nbsp;obinutuzumab (Ven&nbsp;+&nbsp;Obi) [2, 3]. L\u2019association&nbsp;Ven&nbsp;+&nbsp;Obi pour le traitement de premi\u00e8re&nbsp;ligne (1L) de la LLC est d\u00e9sormais \u00e9galement admise par les caisses-maladie depuis le 1<sup>er<\/sup>&nbsp;juillet&nbsp;2025 [1].<\/strong><\/p>\n\n\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fladmission-par-les-caisses-maladie-dun-traitement-de-premiere-ligne-de-la-llc-offre-des-occasions-de-beneficier-dune-plus-longue-periode-sans-traitement-1-2%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>L\u2019inhibiteur de BCL-2 Venclyxto\u00ae (v\u00e9n\u00e9toclax; Ven) est autoris\u00e9 en Suisse en association avec l\u2019obinutuzumab (Obi) depuis le 16&nbsp;novembre&nbsp;2023 comme traitement de premi\u00e8re&nbsp;ligne de la leuc\u00e9mie lympho\u00efde chronique (LLC) [2]. Les&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fladmission-par-les-caisses-maladie-dun-traitement-de-premiere-ligne-de-la-llc-offre-des-occasions-de-beneficier-dune-plus-longue-periode-sans-traitement-1-2%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"author":14,"featured_media":404518,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Sponsored Content: Leuc\u00e9mie lympho\u00efde chronique (LLC)","footnotes":""},"category":[11389],"tags":[],"powerkit_post_featured":[],"class_list":["post-404515","post","type-post","status-publish","format-standard","has-post-thumbnail","category-oncologie","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-12 14:44:22","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":[],"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/404515","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=404515"}],"version-history":[{"count":2,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/404515\/revisions"}],"predecessor-version":[{"id":405632,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/404515\/revisions\/405632"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/404518"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=404515"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=404515"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=404515"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=404515"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}